It is the stage that we make this project recognized and we will finance through ICO. For
the investor, we will spread the project to provide various methods to buy NAM coin, to be sponsored widely, for anyone in the world to purchase coins.
Specifically, it takes the form of remittance from each individual wallet to the project's wallet, exchanged with multi-currency (main virtual currency).
Launch of exchange-listed company's own service, Release of crowd-funding service.
Start of test operation as settlement system Start full-scale operation of the system.
The Tokyo-based company plans to mandate an auditor and a lead underwriter this year for the potential listing. It is in talks with
several Japanese auditors and securities firms to this end, and is receptive to further such approaches, he said.
Proceeds from the potential IPO will be used to expand its business in East and Southeast Asia, he said, discounting the possibility
of a trade sale.
The company is not in need of more financing before going public as it is conducting an initial coin offering (ICO) to raise a total of
JPY 10bn (USD 91m) through the sale of its NAM tokens in Japan, Hong Kong and South Korea. The ICO was launched at the end of
last month and has raised about JPY 1.4bn in Japan so far, according to Nakano.
An estimated 50% of the funds raised from the ICO will be used for further R&D - 20-30% to set up its “NAM AI Clinics,” and 10% to
market its genome testing and health food consulting bots through its franchisees, he said.
NAM AI Clinic consists of the application of an electronic medical record (EMR) system that uses blockchain as well as a patient
interviewing a bot, “Doctor Q”, which enables automated medical follow-ups and advises users on whether they should go to the
doctor based on the diagnosis of 20 symptoms. This is achieved by the user answering questions on the app. It has 600 trial users
for Doctor Q and is targeting 10,000 users by this fiscal year-end, he said.
Expansion of business.
Separately, the company is looking to expand its AI Clinic operation business in Hong Kong, while it targets providing its low-cost
interviewing bots in Indonesia and Vietnam, he added.
It is preparing to set up one NAM AI Clinic in Hong Kong by this fiscal year-end. It could also consider acquisitions of smaller
pharmaceutical product and health food suppliers in Hong Kong to obtain facilities to expand its NAM AI Clinic business there,
The company is not considering setting up a NAM AI Clinic in China due to the difference in medical regulations, but it is exporting
its electrical medical record (EMR) system through its partner Weibo [NASDAQ:WB], he added.
The company owns a marketing and financing branch in Hong Kong, as well as an R&D base in Vietnam.
Its competitor is California-based Alphabet [NASDAQ:GOOGL], which is engaged in the development of EMR systems, surgical
assistive robots and flu-tracking web services, according to Nakano.
NAM was founded last October. It aims to increase its number of employees from 15 to about 50 in 2020, the CEO said.
CEO Nakano and COO Yutaro Nakamura currently hold a 50% stake each.
The company expects to reach sales of JPY 5.3bn in FY19, JPY 19.05bn in FY20 and JPY 36bn in FY21
Our new medical record systems can be used in more than 100 hospitals all over the world. Also NAM AI clinic has more than 100 branches among Japan, Hong Kong, Korea. Also the number of our academic papers in healthcare and AI is more than 20 at this time.
Conducting inbound projects in Japanese, our NAM Token can be used in anywhere in Japan. No matter what kind of industries. Tourism related restaurants and hobbies can be paid by NAM TOKEN.